Neuraxpharm

#European Commission #European Medicines Agency #Minoryx Therapeutics #Neuraxpharm #Neurodegenerative disorders #Neuroscience

EC approves first treatment for rare neurodegenerative disease

The European Commission (EC) has granted marketing authorisation under exceptional circumstances for Nezglyal (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients.  It is approved in patients aged two to 12 years with Gadolinium (Gd)-negative brain lesions and is the first approved pharmacological… Read More

#Editor's Choice #News #Regulatory

The European Medicines Agency in Amsterdam
#European Medicines Agency #Minoryx Therapeutics #Neuraxpharm #Neurodegenerative disorders

Leriglitazone gets positive EU opinion for rare neurodegenerative disease

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional circumstances for Nezglyal (leriglitazone) as a treatment for male cALD patients, aged two to 12 years with gadolinium (Gd) negative brain lesions.   European Commission approval is expected by… Read More

#News #Regulatory

Human brain
#Acquisition #CNS #Excessive Daytime Sleepiness (EDS) #Narcolepsy #Neuraxpharm #Neuroscience #TG Therapeutics

Narcolepsy acquisitions to boost Neuraxpharm’s CNS reach

Pharmaceutical company Neuraxpharm, focused on the treatment of central nervous system (CNS) disorders, has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy. Neuraxpharm has acquired these products in most markets outside the US, excluding the… Read More

#Business & Investment #News

Networked world map
#CNS #Neuraxpharm #Pharmaceuticals

Neuraxpharm expands outside Europe into Brazil and Mexico 

Neuraxpharm Group, a European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has established affiliates in Brazil and Mexico, the two largest pharmaceutical markets in Latin America1, as first steps in its expansion outside of Europe.  As part of the expansion into Brazil, Neuraxpharm has… Read More

#News #Regulatory